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Summary 
What is already known about this topic? 
 Psoriasis of the scalp affects up to 79% of people with chronic plaque psoriasis.  
 Despite the range of treatment options, psoriasis of the scalp is a difficult condition to 
manage.  
What does this study add? 
 Very potent corticosteroids are more effective than potent steroids and vitamin D analogues 
either as monotherapy or combination therapy. However, the atrophic potential of 
corticosteroid treatments for scalp psoriasis remains uncertain. 
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Abstract 
Background 
Chronic plaque psoriasis is the most common type of psoriasis and is characterised by redness, 
thickness and scaling. First line management is with topical treatments.   
Objective 
Our objective was to establish the effectiveness, tolerability and safety of topical treatments for 
people with chronic plaque psoriasis of the scalp, assessing placebo-controlled trials of all 
treatments and head-to-head trials that assessed vitamin D analogues. 
Methods 
As part of a Cochrane review of topical treatments for psoriasis we systematically searched 
electronic databases for randomized controlled trials. The review included 26 randomised controlled 
trials of treatments for psoriasis of the scalp with 8,020 participants. Trials used several measures to 
assess changes in psoriasis severity: these were combined using the standardised mean difference 
metric and interpreted by reporting as a 6-point global improvement score. 
Results 
On effectiveness grounds, very potent or potent steroid treatments should be preferred to vitamin 
D3 analogue with approximately an average 10% additional improvement on a 6-point scale. Vitamin 
D3 analogue combined with potent steroid appears more effective than monotherapy with either 
vitamin D3 or steroids. Rates of withdrawal from treatment and adverse events in trials were 
generally low and similar to those for placebo. There remains uncertainty about the atrophic 
potential of corticosteroid treatments for scalp psoriasis.  
Conclusions 
Corticosteroids are more effective as vitamin D analogues and similarly tolerated. However, further 
research is needed to inform long-term maintenance treatment and provide appropriate safety data. 
 
Key words: Psoriasis; Review; Drug Administration, Topical; Treatment Outcome; Drug Safety 
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Background 
Psoriasis is a chronic inflammatory skin disease with a prevalence ranging from 1-2% in the UK and 
northern European populations1 2 down to 0.1 to 0.3% in the Far East3 and China.4 Chronic plaque 
psoriasis may be localised or widespread and accounts for 90% of psoriasis cases;5 it is characterised 
by red patches of thickened skin (plaques) covered in silver scales. Any area of the body may be 
affected, but the main areas are the knees, elbows, lower back and scalp. There is a wide spectrum 
of disease severity from a single plaque to involvement of more than 90% of the skin surface. 
Psoriasis can lead to social isolation,6 stigmatisation7 and can adversely affect quality of daily life.8-15 
Psoriasis of the scalp affects up to 79% of people with chronic plaque psoriasis; the scalp is typically 
the first area of the body to be affected, and the frequency of involvement increases with the 
duration of the disease.16  
Disease progression is complex and appears to be influenced by many factors including local trauma, 
infections, certain drugs (such as beta-blockers, lithium, chloroquine and non-steroidal anti-
inflammatory drugs (NSAIDs)), the duration of antipsoriatic treatments, endocrine factors, sunlight, 
alcohol, smoking and stress.17 The skin lesions of psoriasis are characterised by cells multiplying too 
quickly (epidermal hyperproliferation), cells not maturing normally (abnormal keratinocyte 
differentiation) and the presence of cells which cause inflammation (a lymphocyte inflammatory 
infiltrate).18-20 Psoriasis is now recognised as an immune-mediated disorder, with tumour necrosis 
factor alpha (TNFα), dendritic cells and T-cells all contributing to its pathogenesis.21 A meta-analysis22 
of three genome-wide association studies (GWAS) identified 15 new chromosomal susceptibility loci 
for psoriasis, bringing the total number of loci known to be associated with psoriasis to 36. Several of 
these loci are involved in the regulation of the skin’s innate immune response. They provide 
confirmation of the role of several existing biologic therapies and provide new targets for drug 
development. 
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Topical treatments are the main therapy for psoriasis of the scalp, whatever the level of disease 
severity.16 They include vitamin D analogues, used alone or in combination with potent 
corticosteroids; potent and very potent corticosteroids; coal tar; and other treatments.23 24 Scalp 
psoriasis is one of the most challenging forms of the disease to manage, because the presence of 
hair makes the use of ointments and cream-based products “difficult and messy”.25 Lotions, 
shampoos, gels and sprays are all used as vehicles for active treatment.  
This paper is based on a Cochrane review26 27 most recently substantially amended in The Cochrane 
Library 2013, Issue (3) (see http://www.thecochranelibrary.com).28 Cochrane reviews are regularly 
updated as new evidence emerges and in response to feedback; the Cochrane Library should be 
consulted for the full and most recent version of the review. 
Objective 
To compare the effectiveness, tolerability and safety of topical treatments for people with chronic 
plaque psoriasis of the scalp relative to placebo, and to compare vitamin D analogues head-to-head 
with other topical treatments.  
Methods 
This research presents a subset of a larger Cochrane review on topical treatments for chronic plaque 
psoriasis (Mason 2013, in press).28 The full review includes 177 studies, reported in 242 articles. The 
methods reported here are those used for the full review, including trials of body and scalp psoriasis.  
 
Inclusion criteria 
We included only randomised controlled trials in the review. Trials could be either placebo-
controlled or have an active comparison with a vitamin D preparation. We selected vitamin D 
analogues for this comparison because they are first-line treatments in many developed countries.29  
Trials of systemic or ultra-violet (phototherapy) treatments with adjunctive topical treatment were 
not eligible for inclusion. We excluded the study if no useful effectiveness, withdrawal or adverse 
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events data were available, either from the published paper or from sponsors or trialists, we 
excluded the study.  
 
Data extraction 
One author extracted study data and assessed study quality. A second author checked these data.  
 
Searches 
Table 1 shows the electronic databases searched in February 2011. Details of the search strategy for 
Medline are available as an online appendix (Ref).  Ongoing studies were identified from the UK 
Clinical Research Network Study Portfolio and the metaRegister of Current Controlled Trials. We 
routinely contacted trialists and companies for missing data.  
TABLE 1 HERE 
Outcomes 
We extracted data from trials on four primary outcomes (Table 2). Trials often reported more than 
one measure, but no trial reported all of the measures. We therefore devised a 'combined endpoint' 
to facilitate treatment comparisons, and use this to report summary findings from the review. We 
constructed the combined endpoint by taking primary outcomes data in the order listed in Table 2, 
according to availability. Thus within-trial differences essentially capture a common construct of 
change in psoriasis severity due to treatment, regardless of the outcome measure used. Additionally 
we extracted data on five secondary outcomes: data on withdrawal due to any cause, to adverse 
events and to treatment failure, as well as adverse events due to local and systemic effects. 
TABLE 2 HERE 
Statistical Methods 
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We analysed and pooled findings using a standardised mean difference (SMD) statistic within a 
random effects model. We report heterogeneity Q (χ2) statistic and I2 statistics, noting heterogeneity 
according to the Cochrane Handbook’s “rough guide to interpretation”: 50% to 90%: may represent 
substantial heterogeneity and 75% to 100% considerable heterogeneity.30  Where studies did not 
report estimates of variance, we derived them from confidence intervals or from P values where 
possible, or imputed them deterministically by pooling the standard deviations of treatment cohorts 
fully reported in trials and adjusted for scale. SMD combined endpoints were transformed back to 
natural units on a 6-point improvement (Investigators Global Assessment of improvement; IAGI) 
scale (ranging from ‘worse’ to ‘clearance’) using pooled IAGI standard deviations. As definitions of 
withdrawal and adverse events vary between trials, data were summarised using a random effects 
risk difference metric.  
 
Interpretation 
Interpreting the weight of evidence in support of a treatment is ultimately arbitrary, nonetheless 
there are two accepted principles (all things being equal): first, consistent findings from multiple 
independent trials provide stronger evidence than one trial alone; and second, trials with larger 
numbers of patients are preferable to smaller ones because of the lower risk of inferential error. 
These two principles are used to interpret available evidence for the clinical management of scalp 
psoriasis. The statistical significance of findings was determined at the 5% level. 
 
Results 
The review included 26 trials of scalp psoriasis:31-56 14 trials were placebo controlled only; 11 
compared vitamin D with other active treatment; and, one additional trial41 reported both placebo-
controlled and active comparisons. Table 3 summarises the characteristics of the scalp trials 
reviewed. 
.  
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TABLE 3 HERE 
Of the 20 trials that reported baseline disease severity, the majority (13/20, 65%) investigated 
moderate to severe psoriasis of the scalp (Figure 1).  
FIGURE 1 HERE 
Treatment duration averaged 7 weeks, but ranged from 2 weeks to 52 weeks. With the exception of 
one within-patient (right-left) study that was published in 1978,47 trials were between-patient 
(parallel group) in design.  
FIGURE 2 HERE 
Figure 2 summarises study quality.  Most trials (73%) were double-blind. Single-blind (investigator 
only; 2 trials) and 'open' (no blinding; 3 trials) studies were typically those in which it was impossible 
to conceal the identity of products being investigated from participants, for example, trials of coal 
tar products, or trials of products comparing different vehicle formulations such as shampoo and 
solution. The majority of studies did not report their methodology in sufficient detail. For instance, 
just 8 trials (31%) clearly reported the randomisation method, and concealment of treatment 
allocation was unclear in 25 trials (96%). In one trial, concealment of treatment allocation was 
‘adequate’ (i.e. the investigator could not foresee treatment assignment). On average, 11% of 
patients were lost to follow up during trials (range 0% to 21%). However, most trials (73%) 
demonstrated that groups were comparable in both clinical and demographic characteristics.  
 
Placebo-controlled trials  
We found placebo-controlled evidence of effectiveness for 11 treatments for scalp psoriasis (Figure 
3). Thirteen between-patient trials and one within-patient trial47 contributed data from 3011 
participants. Patient participation in the trials ranged between two and eight weeks.  
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FIGURE 3 HERE 
The largest treatment effect was observed for the very potent corticosteroid clobetasol propionate, 
reported in 4 trials (SMD -1.57; 95% CI -1.81 to -1.34; I² = 43.3%; N=788), which improved 
participants’ psoriasis by 1.9 points on a 6-point global improvement scale. The potent steroid 
betamethasone dipropionate, reported in 2 trials (SMD -1.09; 95% CI -1.29 to -0.90; I² = 0%; N=712), 
improved psoriasis by 1.3 points on a 6-point global improvement scale. Other very potent steroids 
(amcinonide, halcinonide and fluocinolone acetonide [with occlusion]) and potent steroids 
(betamethasone valerate, betamethasone-17, 21-dipropionate [plus salicylic acid] were reported 
only in single trials with smaller patient numbers (and thus less precision) but with similar benefits.   
 
The vitamin-D3 analogue calcipotriol demonstrated a modest benefit against placebo although 
findings were heterogeneous (2 trials; I²: 69.2%; N=457) with the only trial of significant size 
suggesting a 0.6 point improvement on a 6-point global improvement scale. Calcipotriol combined 
with betamethasone dipropionate suggested significant benefit against placebo but substantial 
heterogeneity (2 trials; I² = 90%; N=854), with individual trials reporting 0.7 and 1.5 point gains on a 
6-point scale.  
 
Two further treatments, each assessed by one small trial, were no more effective than placebo 
(ciclopirox olamine shampoo, and salicylic acid).  
 
Placebo-controlled trials do not provide adequately precise findings to rank all available treatment 
options using indirect (placebo-controlled) comparisons. However available evidence suggests a 
ranking of monotherapies for effectiveness of clobetasol propionate (very potent corticosteroid), 
betamethasone dipropionate (potent steroid) and then calcipotriol (vitamin-D3 analogue).  
 
10 
 
Head-to-head trials 
Direct (head-to-head) comparisons were made of vitamin D analogues (alone or in combination) 
with other treatments (Figure 4). Twelve studies contributed data from 5413 patients. Trial 
durations ranged from 4 to 8 weeks in eleven studies, but the duration was 52 weeks in one trial.48  
FIGURE 4 HERE 
Trials comparing vitamin D analogue monotherapy with very potent or potent steroid monotherapy 
consistently favoured corticosteroid treatment. One small trial comparing calcipotriol and clobetasol 
propionate supported the indirect comparison of these two treatments (SMD 0.37; 95% CI 0.05 to 
0.69; N=151) with a 0.5 point gain on a 6-point global improvement scale favouring clobetasol 
propionate. Two trials comparing calcipotriol with betamethasone dipropionate (SMD 0.48; 95% CI 
0.32 to 0.64; I2 = 60%, N=1676) and with betamethasone valerate (SMD 0.37; 95% CI 0.20 to 0.55; I2 
= 0%, N=510) favoured corticosteroid treatment with 0.6 and 0.5 point gains respectively on a 6-
point global improvement scale. We also pooled the trials comparing vitamin D analogues with 
potent or very potent steroids (SMD 0.45; 95% CI 0.36 to 0.53; I2 = 1%, N=2337).  Thus 
corticosteroids provided approximately a 10% improvement in average scores compared with 
calcipotriol on a 6-point global improvement scale. 
 
Combination therapy involving vitamin D analogue and corticosteroid offered a small advantage 
over corticosteroid alone (SMD -0.18; 95% CI -0.26 to -0.10; I2 = 0%, N=2444) of 0.2 points on a 6-
point global improvement scale. Combination therapy involving vitamin D analogue and 
corticosteroid offered an improvement over calcipotriol alone, although findings were 
heterogeneous (4 trials; I2 = 82%, N=2581), with gains of 0.5 to 1.2 points on a 6-point global 
improvement scale.  
 
11 
 
Findings were heterogeneous for trials comparing calcipotriol with coal tar polytherapy (3 trials; I2 = 
90%, N=835), ranging from no benefit to 1.2 points on a 6-point global improvement scale.  
 
Withdrawals 
For most treatments, rates of total withdrawal, withdrawal due to adverse events, withdrawal due 
to treatment failure were similar to those for placebo (‘placebo-like’) and not statistically 
significantly different; however, evidence for individual treatments was typically informed by 
individual small trials. When pooled findings from multiple trials were assessed, placebo-like 
withdrawal was only supported for calcipotriol (3 trials; I2=0%; N=517). Overall, evidence on 
clobetasol propionate suggested the withdrawal rate was similar to placebo but findings were 
heterogeneous (5 trials; I2=89%; N=1006). There was evidence from two trials that withdrawal rates 
for combined calcipotriol and betamethasone valerate was lower than placebo (RD -9%; 95%CI -16% 
to -3%; 2 trials; I2=0%; N=854).  
 
Withdrawal rates for head-to-head comparisons of treatments consistently suggested slightly lower 
withdrawal from corticosteroids than from calcipotriol although this finding was not significant at 
the level of individual treatments. There was some evidence to suggest greater withdrawal with 
calcipotriol than combined calcipotriol and betamethasone valerate, although findings were 
heterogeneous (5 trials; I2=79%; N=2847), with higher withdrawal for calcipotriol varying from 5% to 
18%. 
 
Adverse events 
Rates of local adverse events were very low and placebo-like, although only consistently informed by 
multiple trials and substantial numbers of patients for calcipotriol and clobetasol propionate. 
Evidence from head-to-head trials supports the central finding of no important differences between 
treatments. Calcipotriol monotherapy, when compared with combined calcipotriol and 
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betamethasone, was associated with higher adverse event rates although some of these findings 
were heterogeneous. 
 
Seven of the 19 trials that included a corticosteroid (alone or in combination) reported that atrophy 
had been assessed. 33 40 46 50-52 57 Four trials reported no atrophy: treatments tested in these trials 
included clobetasol propionate shampoo,40 potent corticosteroids,50 and combination treatment 
with calcipotriol and betamethasone dipropionate.46 48 The remaining three trials reported instances 
of atrophy,33 51 52 all investigating clobetasol propionate. The method used to assess atrophy was 
described in only two trials and was unclear in all other trials.  In Luger 2008,48 a 52 week trial that 
compared combination therapy with vitamin D monotherapy, an independent adjudication 
committee decided whether the cases observed by the investigator were likely to be attributable to 
treatment.  Poulin 2010 relied on self-report by study participants.51 
 
Discussion 
This review identified 26 trials of scalp psoriasis with 8,020 participants, with most trials 
investigating moderate to severe disease. Despite a range of topical therapeutic options there is 
substantial evidence for only a few treatment options: clobetasol propionate, betamethasone 
dipropionate, betamethasone valerate, calcipotriol and calcipotriol combined with potent steroid. 
Other corticosteroids suggest similar performance although findings are imprecise or based on 
findings of single trials. We did not find evidence to support the first-line use of a tar-based shampoo 
(with or without a keratolytic, such as salicylic acid, for significant scaling), a current formulary 
recommendation.58 
 
All treatments were more effective than placebo, meaning that all may have clinical value in the 
management of individual patients. Corticosteroids out-performed the vitamin D3 analogue 
calcipotriol: although indirect evidence from placebo-controlled trials favoured very potent above 
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potent steroids this was not apparent in head-to-head evidence with calcipotriol. However, we did 
not review very potent compared with potent steroid treatment directly. Combined treatment with 
vitamin D3 analogue and corticosteroid offered a small advantage over steroid alone and might be a 
treatment option in treatment resistant scalp psoriasis.  
 
In overview, withdrawal and adverse event rates were very low in absolute terms, placebo-like and 
similar when comparing between treatments. There is some evidence that combined calcipotriol and 
betamethasone dipropionate is better tolerated than calcipotriol alone. Evidence presented in trials 
is insufficient to make any statement about corticosteroid-induced skin atrophy, and it is possible 
that cases of atrophy have gone unreported. 
 
A limitation of the analysis is that with relatively few trials informing comparisons it was not possible 
to explore heterogeneous findings meaningfully. Heterogeneity may arise due to methodological or 
clinical diversity between trials. Trials were not often adequately reported so methodological 
variation cannot be excluded. Variations in age, gender, severity and ethnicity are examples of 
potential clinical diversity that may promote heterogeneous findings. For example Tyring 201054 and 
Jemec 200841 were both 8-week, double blind parallel group trials comparing combination therapy 
with its vehicle (placebo gel).  Both trials found combination treatment to be significantly more 
effective than placebo (Figure 1), but the effect sizes were qualitatively different: -0.62 [-0.98, -0.27]) 
and -1.28 [-1.48, -1.08].  In both trials, around 72% of patients on active treatment responded (very 
mild disease or clearance) but placebo response differed (41% vs. 23%). Tyring 2010 recruited 
Hispanic, Latino, Black and African American patients, 63% male and none with mild disease. Jemec 
2008 recruited predominantly white patients (96%), 45% male; 6.5% with mild disease, and 37.3% 
(vs. 19.8%) with severe or very severe disease.  Thus there are multiple candidates for 
heterogeneous findings.  
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Conclusions 
There is evidence for the effectiveness and tolerability of a range of topical therapeutic options for 
scalp psoriasis, although this evidence is adequate for a limited number of treatments. On 
effectiveness grounds, very potent (clobetasol propionate) or potent steroid treatments should be 
preferred to vitamin D3 analogue (calcipotriol). Calcipotriol combined with potent steroid may be a 
therapeutic option in cases that do not respond to monotherapy. The atrophic potential of 
corticosteroid treatments for scalp psoriasis remains unclear, and future studies should report cases 
of atrophy consistently and using robust assessment methods. 
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Table 3: Descriptive statistics of the study characteristics 
Number of studies 26 
Number of participants 8,020 
Trial sample size [mean, range] 308 [22, 1505] 
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Participant gender [% male: mean] 46.6% b 
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Study design 
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  Between patient 25 
Within patient 1 
  Method of randomisation 
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Computerised 7 
Not reported 18 
Concealment of treatment allocation 
 Adequate 1 
Unclear 25 
Blinding 
 Double blind 19 
Single blind 2 
Open 3 
Not reported 2 
Baseline comparability demonstrated 
 Yes 19 
Partial 2 
Not reported / unclear 5 
Note: summary statistics are based on data from 26 studies, with the following exceptions: 
 age a [N=19], gender b [N=21] and duration of follow up c [N=25]. 
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Figure 1: Variation in participants’ disease severity across the 26 trials of scalp psoriasis 
 
 
 
Figure 2: Study quality, shown using the ‘Risk of bias graph’ 
 
Note: review authors' judgements about each risk of bias item are presented as percentages across 
all included studies 
 
 
Figure 3: Placebo-controlled trials of scalp psoriasis: treatment effectiveness 
 
Figure 4: Active-controlled trials of scalp psoriasis: treatment effectiveness 
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